We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $163M
1-Year Est. Return 240.43%
This Fund
S&P 500
This Quarter Est. Return
+5.2%
1 Year Est. Return
+240.43%
3 Year Est. Return
+409.28%
5 Year Est. Return
+142.09%
10 Year Est. Return
+4,071.98%
AUM
$78.8M
AUM Growth
-$34.9M
Cap. Flow
-$37.8M
Cap. Flow %
-47.9%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$5.61M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$34.9M
2
INGN icon
Inogen
INGN
+$4.97M
3
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 93.19%
2 Miscellaneous 6.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
$35.8M 45.41%
407,416
-407,417
-50% -$34.9M
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$27.1M 34.41%
1,092,152
– –
AKAO
3
DELISTED
Achaogen Inc
AKAO
$7.73M 9.8%
1,281,152
– –
BITI
4
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$5.37M 6.81%
+268,672
New +$5.61M
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$2.82M 3.58%
1,048,601
– –
INGN icon
6
Inogen
INGN
$139M
– –
-155,284
Closed -$4.97M
KYTH
7
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-70,376
Closed -$3.53M

Similar funds

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GF
Gimbal Financial Carmel, Indiana $163M AUM
ACM
Arrington Capital Management Miami, Florida $163M AUM
KFS
Krane Financial Solutions Calabasas, California $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
GCM
Generation Capital Management Pittsford, New York $163M AUM 42.22% 1-Year Est. Return

Versant Venture Management's Q2 2015 Portfolio in Review

As of Q2 2015, Versant Venture Management held 7 positions worth $78.8M, down 31% from $114M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $37.8M in Q2 2015, closing 2 positions and reducing 1 holding. Its most notable exit was Inogen, an estimated $4.97M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 97% a quarter earlier, followed by Miscellaneous.

Against the trend, Versant Venture Management opened a new position in BIOTIE THERAPIES CORP SPONSORED ADR worth $5.37M.

  • Versant Venture Management's largest Q2 2015 buy was BIOTIE THERAPIES CORP SPONSORED ADR: 268,672 shares worth $5.37M.
  • Versant Venture Management's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $34.9M.
  • Versant Venture Management fully exited Inogen in Q2 2015, selling an estimated $4.97M.
  • Versant Venture Management's ten largest holdings make up 100% of its $78.8M portfolio in Q2 2015.
  • Versant Venture Management opened 1 new position and closed 2 in Q2 2015.
  • Versant Venture Management's portfolio value fell 31% quarter-over-quarter to $78.8M.

Based on Versant Venture Management's 13F filing for Q2 2015, filed 15 Jul 2015.